Anales de la RANM

49 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LINFOMA NO HODGKIN FOLICULAR Fernández-Rañada de la Gándara JM An RANM. 2025;142(01): 41 - 50 No existen datos comparativos de la inmunoterapia T frente a los procedimientos de trasplante tanto autólogo como alogénico. El papel del autólogo parece claro en el tratamiento de segunda línea del LF (42). Es posible el carácter curativo del trasplante alogénico en una población de pacientes con LF. La edad y las complicaciones clínicas del alotras- plante han frenado su uso que en la actualidad es minoritario (43). El papel definitivo tanto de los anticuerpos biespecíficos como de la terapia con anti-CD19 CAR-T Cells requiere del conocimiento de muchos de los estudios hoy en desarrollo. El concepto de “curación funcional” hoy en día puede aplicarse a cierta proporción de enfermos con LF. Quizá la “curación real” sea un objetivo próximo con los tratamientos innovativos. DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en el presente trabajo. BIBLIOGRAFÍA 1. Kurtz KS, Kalmbach S, Ott M, et al. Follicular Lymphoma in the 5th Edition of the WHO- classification of Haematolymphoid Neoplasms. Updated classification and New Biological Data. Cancers. 2023; 15:785-804. 2. Henopp T, Quintanilla-Martínez L, Fend F, et al. Prevalence of follicular lymphoma in situ in consecutively analysed reactive lymph nodes. Histopathology. 2011; 59:139-142. 3. Louissaint A, Ackerman AM, Dias-Santagata D, et al. Pediatric-type nodal follicular lym- phoma: an indolent clonal proliferation in children and adults with high proliferation in- dex and no BCL2 rearrangement. Blood. 2012; 120:2395-2404. 4. Takata K, Okada H, Ohmiya N, et al. Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct enti- ty: a multicenter, retrospective analysis in Ja- pan. Cancer Sci. 2011; 102:1532-1536. 5. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B- cell lymphoma: The Italian Study Group for Cutaneous Lymphomas. J. Clin. Oncol. 2006; 24:1376-1382. 6. Horming SJ, Rosenberg SA. The natural his- tory of initially untreated low-grade non- Hodgkin's lymphomas. N Eng J Med. 1984; 311:1471-1475. 7. Horn H, Schmelter C, Leich E, et al. Follicular lymphoma grade 3B is a distinct neoplasm ac- cording to cytogenetic and immunohistochemi- cal profiles. Haematologica. 2011; 96:1327-1334. 8. Rowley JD. Chromosome studies in the non- Hodgkin's lymphomas: the role of the 14;18 translocation. J Clin Oncol. 1988; 6:919-925. 9. Rutherford SC, Herold M, Hiddemann W, et al. Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. Blood Adv. 2020; 4:1589-1593. 10. Rutherford SC, Li V, Ghione P, et al. Bone marrow biopsies do not impact response as- sessment for follicular lymphoma patients treated on clinical trials. Br J Haematol. 2017; 179:242-245. 11. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, sta- ging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32:3059- 3068. 12. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and respon- se assessment of lymphoma: consensus of the International Conference on Malignant Lym- phomas Imaging Working Group. J Clin Oncol. 2014; 32:3048-3058. 13. Solal-Céligny P, Roy P, Colombat P, et al. Fo- llicular lymphoma international prognostic in- dex. Blood. 2004; 104:1258-1265. 14. Kimby E, Lockmer S, Holte H, et al. The sim- plified follicular lymphoma PRIMA Prognos- tic index is useful in patients wiht first-line chemo-free Rituximab-based therapy. Br J Haematol. 2020; 191:738-747. 15. Friedberg JW, Byrtek M, Link BK, et al. Effec- tiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012; 30:3368-3375. 16. Cartron G, Bachy E, Tilly H, et al. Randomi- zed Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. J Clin Oncol. 2023; 41:3523-3533. 17. Townsend W, Hiddemann W, Buske C, et al. Obinutuzumab versus Rituximab Immunoche- motherapy in Previously Untreated iNHL: Fi- nal Results From the GALLIUM Study. Hemas- phere. 2023; 30;7(7):e919.doi. 18. Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018; 36:2395-2404. 19. Strati P, Jain P, Johnson RJ, et al. Long-term fo- llow-up of lenalidomide and rituximab as ini- tial treatment of follicular lymphoma. Blood. 2021; 137:1124-1129. 20. Bachy E, Houot R, Feugier P, et al. Obinutuzu- mab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of sys- temic therapy: a LYSA study. Blood. 2022; 139:2338-2346. 21. Morschhauser F, Nastoupil L, Feugier P, et al. Six-Year Results From RELEVANCE Lenalido- mide Plus Rituximab (R2) Versus Rituximab- Chemotherapy Followed by Rituximab Main- tenance in Untreated Advanced Follicular Lymphoma. J Clin Oncol. 2022; 40:3239-3245.